Recent publications
Article
Aiyegbusi, OL, Ferrante di Ruffano, L, Retzer, A, Newsome, P, Buckley, C & Calvert, M 2022, 'Outcome selection for tissue-agnostic drug trials for immune mediated inflammatory diseases: a systematic review of core outcome sets and regulatory guidance', Trials, vol. 23, 42. https://doi.org/10.1186/s13063-022-06000-w
Macpherson, K, Aiyegbusi, OL, Elston, L, Myles, S, Washington, J, Sungum , N, Briggs, M, Newsome, P & Calvert, M 2021, 'A scoping review of patient and public perspectives on cell and gene therapies', Regenerative Medicine . https://doi.org/10.2217/rme-2020-0181
Dhaliwal, A, Williams, FR, Quinlan, JI, Allen, SL, Greig, C, Filer, A, Raza, K, Ghosh, S, Lavery, GG, Newsome, PN, Choudhary, S, Breen, L, Armstrong, MJ, Elsharkawy, AM & Lord, JM 2021, 'Evaluation of the mechanisms of sarcopenia in chronic inflammatory disease: protocol for a prospective cohort study', Skeletal Muscle, vol. 11, no. 1, 27. https://doi.org/10.1186/s13395-021-00282-5
CATALYST investigators, Fisher, B, Veenith, T, Slade, D, Gaskell, C, Rowland, M, Whitehouse, T, Scriven, J, Parekh, D, Balasubramaniam, M, Cooke, G, Morley, N, Gabriel, Z, Wise, M, Porter, J, McShane, H, Ho, L-P, Newsome, P, Rowe, A, Sharpe, R, Thickett, D, Bion, J, Gates, S, Richards, D & Kearns, P 2021, 'Namilumab or infliximab compared with standard of care in hospitalised patients with COVID-19 (CATALYST): a randomised, multicentre, multi-arm, multistage, open-label, adaptive, phase 2, proof-of-concept trial', The Lancet Respiratory Medicine. https://doi.org/10.1016/S2213-2600(21)00460-4
Newsome, PN & Berg, T 2020, '2020 - A new decade of innovation for EASL.', Journal of Hepatology, vol. 72, no. 1, pp. 8. https://doi.org/10.1016/j.jhep.2019.10.016
Eslam, M, Newsome, PN, Sarin, SK, Anstee, QM, Targher, G, Romero-gomez, M, Zelber-sagi, S, Wai-sun Wong, V, Dufour, J, Schattenberg, JM, Kawaguchi, T, Arrese, M, Valenti, L, Shiha, G, Tiribelli, C, Yki-järvinen, H, Fan, J, Grønbæk, H, Yilmaz, Y, Cortez-pinto, H, Oliveira, CP, Bedossa, P, Adams, LA, Zheng, M, Fouad, Y, Chan, W, Mendez-sanchez, N, Ahn, SH, Castera, L, Bugianesi, E, Ratziu, V & George, J 2020, 'A new definition for metabolic dysfunction-associated fatty liver disease: an international expert consensus statement', Journal of Hepatology, vol. 73, no. 1, pp. 202-209. https://doi.org/10.1016/j.jhep.2020.03.039
NN9931-4296 Investigators 2020, 'A placebo-controlled trial of subcutaneous semaglutide in nonalcoholic steatohepatitis', New England Journal of Medicine. https://doi.org/10.1056/NEJMoa2028395
Sheriff, L, Khan, RS, Saborano, R, Wilkin, R, Luu, N, Gunther, UL, Hubscher, SG, Newsome, PN & Lalor, PF 2020, 'Alcoholic hepatitis and metabolic disturbance in female mice: a more tractable model than Nrf2-/- animals', Disease Models & Mechanisms, vol. 13, no. 12, dmm046383. https://doi.org/10.1242/dmm.046383
Taylor, RS, Taylor, RJ, Bayliss, S, Hagström, H, Nasr, P, Schattenberg, JM, Ishigami, M, Toyoda, H, Wai-sun Wong, V, Peleg, N, Shlomai, A, Sebastiani, G, Seko, Y, Bhala, N, Younossi, ZM, Anstee, QM, Mcpherson, S & Newsome, PN 2020, 'Association between fibrosis stage and outcomes of patients with nonalcoholic fatty liver disease: a systematic review and meta-analysis', Gastroenterology, vol. 158, no. 6, pp. 1611-1625.e12. https://doi.org/10.1053/j.gastro.2020.01.043, https://doi.org/10.1053/j.gastro.2020.01.043
Newsome, P, Sasso, M, Deeks, J, Paredes, A, Boursier, J, Chan, WK, Yilmaz, Y, Czernichow, S, Zheng, MH, Wong, VW, Allison, M, Tsochatzis, E, Anstee, QM, Sheridan, DA, Eddowes, PJ, Guha, IN, Cobbold, JF, Paradis, V, Bedossa, P, Miette, V, Fournier-Poizat, C, Sandrin, L & Harison, SA 2020, 'FibroScan-AST (FAST) score for the non-invasive identification of patients with non-alcoholic steatohepatitis with significant activity and fibrosis: a prospective derivation and global validation study', The Lancet Gastroenterology & Hepatology, vol. 5, no. 4, pp. 362-373. https://doi.org/10.1016/s2468-1253(19)30383-8
Comment/debate
Retzer, A, Aiyegbusi, OL, Rowe, A, Newsome, P, Douglas-Pugh, J, Khan, S, Mittal, S, Wilson, R, O'Connor, D, Campbell, L, Mitchell, SA & Calvert, M 2022, 'The value of patient-reported outcomes in early phase clinical trials', Nature Medicine, vol. 28, pp. 18–20. https://doi.org/10.1038/s41591-021-01648-4
Editorial
Horn, P & Newsome, PN 2020, 'Editorial: re-thinking cardiovascular risk factors in NAFLD with advanced fibrosis?', Alimentary Pharmacology & Therapeutics, vol. 51, no. 10, pp. 987-988. https://doi.org/10.1111/apt.15682
Preprint
Fisher, BA, Veenith, T, Slade, D, Gaskell, C, Rowland, M, Whitehouse, T, Scriven, J, Parekh, D, Balasubramaniam, MS, Cooke, G, Morley, N, Gabriel, Z, Wise, MP, Porter, J, McShane, H, Ho, L-P, Newsome, PN, Rowe, A, Sharpe, R, Thickett, DR, Bion, J, Gates, S, Richards, D & Kearns, P 2021 'Namilumab or infliximab compared to standard of care in hospitalised patients with COVID-19 (CATALYST): a phase 2 randomised adaptive trial' medRxiv, pp. 1-26. https://doi.org/10.1101/2021.06.02.21258204
Review article
Boettler, T, Newsome, PN, Mondelli, MU, Maticic, M, Cordero, E, Cornberg, M & Berg, T 2020, 'Care of patients with liver disease during the COVID-19 pandemic: EASL-ESCMID position paper.', JHEP Reports, vol. 2, no. 3, pp. 100113. https://doi.org/10.1016/j.jhepr.2020.100113
Horn, P & Newsome, PN 2020, 'Emerging therapeutic targets for NASH: key innovations at the preclinical level.', Expert Opinion on Therapeutic Targets, vol. 24, no. 3, pp. 175-186. https://doi.org/10.1080/14728222.2020.1728742
View all publications in research portal